PCSK9 Expert Opinions Prof. John Kastelein explains the most important points from FOURIER and SPIRE 1&2. He argues that there can no longer be any doubt that lowering LDL is crucial for CVD prevention.
PCSK9 Expert Opinions Prof. John Chapman gives his personal views on the results of FOURIER and SPIRE 1&2. Key question is whether in the light of the new data, the LDL-c goal will be maintained or lowered in high-CV risk individuals.
ACC 2017 AF patients starting digoxin treatment showed increased mortality, especially in the first 6 months, irrespective of the coexistence of HF, and digoxin concentrations >1.2 ng/ml should be avoided.
ACC 2017 First study investigating the effects of statins on the CNS using fMRI, showed few differences between atorvastatin 80 mg and placebo in standardised neuropsychological tests.
ACC 2017 Paroxysmal AF was associated with a higher risk of HF hospitalisation and stroke, while new-onset AF was associated with a higher risk of HF hospitalisation, death and stroke.
ACC 2017 In addition to its cardiovascular benefits, sacubitril/valsartan also reduces HbA1c levels, compared to enalapril.
ACC 2017 In non-cardiac surgery patients, a peak postoperative hsTnT measurement ≥ 20 ng/L and an absolute change of ≥ 5 ng/L was significantly associated with 30-day mortality.
ACC 2017 In AF patients undergoing ablation, periprocedural anticoagulation with uninterrupted dabigatran (150 mg twice daily) compared with warfarin was associated with fewer bleeding complications.
ACC 2017 The REACH trial demonstrated that after 12 months of use of an e-counselling programme, hypertensives showed 10 mmHg lower SBP and improvement of other risk factors.
ACC 2017 In STEMI patients with multi-vessel disease, fractional flow reserve-guided complete revascularisation of non–infarct-related lesions during primary PCI, reduced the risk of MACCE.
ACC 2017 In post-ACS patients with at least one site with percent atheroma volume >30% in the proximal 10 mm of the target vessel, CER-001 did not lead to significant plaque regression in the CARAT study.
ACC 2017 A safety study of rivaroxaban versus aspirin on top of P2Y12 therapy in ACS patients, showed that this dual antithrombotic regimen had a similar risk of clinically significant bleeding.